The mandatory CMS TEAM program begins next year. Are you ready? As hospitals consider their options for addressing the mandate, here are some actions to consider. The post Value-Based Care Gets Real appeared first on MedCity News.
KFF Health News Midwest correspondent Cara Anthony and Emily Kwong, host of NPR’s podcast “Shortwave,” talk about Black families living in the aftermath of lynchings and police killings in their communities. Anthony shares her southeastern Missouri-based reporting from “Silence in Sikeston,” a documentary film, podcast, and print reporting project. She discusses the latest research on…
Nearly seven months after the fatal shooting of an insurance CEO in New York drew widespread attention to health insurers’ practice of denying or delaying doctor-ordered care, the largest U.S. insurers agreed Monday to streamline their often cumbersome preapproval system. Dozens of insurance companies, including Cigna, Aetna, Humana, and UnitedHealthcare, agreed to several measures, which…
Simple: get people vaccinated. Dr. Oz agrees. The New York Times reports: Dr. Oz, the Centers for Medicare and Medicaid Services director, told CNN on Sunday that there was a simple solution to the raging measles outbreak in South Carolina, which has infected more than 900 people and become the largest U.S. outbreak in recent…
KFF is tracking the Medicare provisions included in the legislation approved by the Budget Committee compared to current law
UniQure plans a first quarter 2026 FDA submission for AMT-130 as a treatment for Huntington’s disease. This gene therapy delivers microRNA designed to silence the mutated gene that produces a protein driving this disorder, which so far has no FDA-approved therapies. The post UniQure Gene Therapy’s Clinical Trial Results Keep It on Path to Become…
AbbVie has acquired rights to a multispecific antibody that IGI Therapeutics designed to bind to three targets to treat multiple myeloma. Early Phase 1 results showed encouraging responses in a heavily pretreated patient population and a favorable safety profile. The post AbbVie Pays $700M for Drug Engineered to Overcome Resistance in Multiple Myeloma appeared first…
We must consider the broader social and structural context — recognizing that poverty, social deprivation, and economic instability are not merely relevant factors, but necessary considerations in developing effective, equitable interventions. The post From Transfers to Treatment: Bridging Social Policy and Substance Use Treatment appeared first on MedCity News.
Keros Therapeutics will present Phase 2 data for the drug, elritercept, at the annual meeting of the American Society of Hematology. Meanwhile, the Takeda deal enables Keros to focus on two wholly owned assets, one of which could compete with a Merck drug approved earlier this year. The post Takeda Pays $200M for Keros Therapeutics…
These recommendations on how to care for babies who fail newborn screenings offer valuable lessons for public health officials, clinicians, and families. The post Beyond Newborn Screening: Four Essential Factors in Congenital Disease Care appeared first on MedCity News.